NCATS May Consider Requesting “Active” Compounds For Repurposing Program
Executive Summary
With its first set of grants funded, NCATS wonders whether it should try to solicit repurposing candidates that are still being worked on, rather than only using those that have been shelved.
You may also be interested in...
Paladin’s Impavido Could Set A Price Tag For Priority Review Vouchers
Approval of the leishmaniasis treatment by its December user fee date would give the Canadian sponsor a voucher for a priority review, which it is likely to sell to another company.
NIH Drug Repurposing Program Produces Surprise Overlaps
Crowdsourcing among researchers produces several applications proposing to test a few compounds in the NCATS repurposing library for use in multiple new indications, which officials did not expect.
Inside US FDA’s Return To In-Person Meetings
In an interview, OND Deputy Director of Operations Kevin Bugin describes how FDA might be able to "accelerate" the transition back to in-person meetings if the initial phase with Type A and BPD Type 1 meetings goes well. But there is still no plan to return to in-person advisory committees.